Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net ...

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) ...

Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical” or "the Company”, "we”, or "our”), a commercial-stage ...

Q3 2024 Earnings Call Transcript November 11, 2024 Operator: Thank you for standing by. My name is John, and I’ll be your ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

ENDOTHIRD-QUARTER FINANCIAL PERFORMANCE (in thousands)   CONSOLIDATED RESULTS Total revenues in third-quarter 2024 were$427 million, a decrease of 6% compared to$452 millionin third-quarter 2023. This ...

These risks are described in the cautionary note regarding forward-looking statements, risk factors and management’s discussion and analysis of financial condition and results of operations sections ...

We encourage you to review the information in today's press release and presentation as well as in our quarterly report on Form 10-Q that ... 2024 LDD launches and generic scripts.

Detailed price information for Amarin Corp ADR (AMRN-Q) from The Globe and Mail including charting and trades.

Third Quarter Total Net Product Sales of $28.7 MillionRolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 ...

Third quarter results included the following highlights (our discussion below focuses on a comparison of third quarter 2024 to second quarter 2024 given the acquisition of Spectrum and the generic ...

Received tentative approval from the FDA for YUTREPIATM (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) ...